Janssen Biotech acquired a worldwide license to Alligator Bioscience’s Phase I immunotherapy ADC-1013, an agonistic monoclonal antibody that targets CD40, an immuno-stimulatory receptor found on antigen-presenting cells, which can spur an increase in T cells attacking a tumor. Continue reading
![](https://blogs.shu.edu/cancer/files/2014/07/cancerBiology180x110.jpg)